%0 Generic %A Li, Tian-Xiao %A Gao, Bu-Lang %A Cai, Dong-Yang %A Wang, Zi-Liang %A Zhu, Liang-Fu %A Xue, Jiang-Yu %A Bai, Wei-Xing %A He, Ying-Kun %A Li, Li %D 2015 %T Disabling or fatal stroke rate within and beyond 30 days in the SAMMPRIS study. %U https://plos.figshare.com/articles/dataset/_Disabling_or_fatal_stroke_rate_within_and_beyond_30_days_in_the_SAMMPRIS_study_/1560373 %R 10.1371/journal.pone.0139377.t005 %2 https://plos.figshare.com/ndownloader/files/2293830 %K intracranial atherosclerotic stenosis %K lt %K ias %K stroke rate %K hemorrhagic stroke rate %K intracranial Wingspan stenting %K Single Medical Center PurposeTo %K 433 Patients Treated %K basilar artery area %K perioperative stroke rate %K MethodsBetween July 2007 %X

Note:

# The disabling or fatal stroke rates within 30 days could be found in Table 3 in reference 8.

* The disabling or fatal stroke rates at the end of 32.4 months of follow-up for both groups could be found in Table 3 in reference 9.

** The number of patients with disabling or fatal stroke beyond 30 days was 21–16 = 5 for the PTAS group but 18–4 = 14 for the MED group, whereas the number of patients who finished the follow-up was 191 for the PTAS group and 210 for the MED group (see the Results of reference 9). PTAS: percutaneous transluminal angioplasty and stenting; MED: medical management group.

Disabling or fatal stroke rate within and beyond 30 days in the SAMMPRIS study.

%I PLOS ONE